BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, December 5, 2019 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the compensation committee of BridgeBio’s board of directors granted eight new employees options to purchase an aggregate of 62,745 shares of the Company’s common stock with a per […]

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission Of New Drug Application With The U.S. FDA For BBP-870 For The Treatment Of MoCD Type A

BOSTON, December 3, 2019 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for fosdenopterin (BBP-870/ORGN001) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. Currently, there are no approved therapies that […]

PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

– Trial rapidly enrolled in 8 months – Trial size expanded to accommodate 24 more patients than planned SAN FRANCISCO – December 2, 2019 – PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, November 27, 2019 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its Chief Operating Officer, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; and one additional employee, on November 13, 2019. The Company granted Mr. Stolz (i) non-qualified stock […]

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated Participants in the ATTR-ACT Study Near-complete Stabilization of TTR Maintained in Participants Throughout Duration of Study […]

BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

-Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolio -Delivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2i -Ended quarter with $446.1 million in cash, cash equivalents and marketable securities, excluding Eidos Recent Highlights: BBP-831 – FGFR1-3 inhibitor for achondroplasia: Initiated PROPEL, a prospective observational study in children with […]

BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

Preclinical data shows promise for gene therapy candidates for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (BBP-631) and Canavan disease (BBP-812) Natural history clinical study for Canavan disease is currently enrolling IND submissions for both gene therapy product candidates anticipated in 2020 SAN FRANCISCO – October 22, 2019 – BridgeBio Pharma, Inc. (NASDAQ:BBIO) today announced […]

QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia

Data presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting Infigratinib showed improvements in nine measures of bone development in the Fgfr3Y367C/+ mouse model of achondroplasia at a low dose Observational study (The PROPEL Trial) is currently enrolling children age 2.5-10 years and planned submission of an investigational new drug application remains […]

BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition PALO ALTO – October 14, 2019 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed […]

Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

Preclinical study designed to test investigational agent infigratinib for the treatment of glioblastoma. (PHOENIX, AZ — Sept. 24, 2019) — The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment […]